847499-27-8 Usage
Description
CEP-18770 is a small molecule compound that has been shown to have potential therapeutic effects in various applications.
Uses
Used in Pharmaceutical Industry:
CEP-18770 is used as a proteasome inhibitor for its ability to down-modulate NF-κB, induce apoptosis, inhibit angiogenesis, and prevent M-CSF-RANKL-induced osteoclastogenesis. It has demonstrated efficacy in inhibiting the proliferation of multiple myeloma cell lines and a panel of human hematologic and solid tumor cell lines.
Used in Autoimmune Disease Treatment:
In a mouse model of fatal lupus nephritis, CEP-18770 has been shown to reduce serum levels of circulating cytokines, prevent renal tissue damage, and increase lifespan, making it a potential candidate for the treatment of autoimmune diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 847499-27-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,7,4,9 and 9 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 847499-27:
(8*8)+(7*4)+(6*7)+(5*4)+(4*9)+(3*9)+(2*2)+(1*7)=228
228 % 10 = 8
So 847499-27-8 is a valid CAS Registry Number.
847499-27-8Relevant articles and documents
Proteasome inhibitor delanzomib for use in the treatment of lupus
-
Page/Page column 19, (2016/06/06)
The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject Compound A.
PROTEASOME INHIBITORS AND PROCESSES FOR THEIR PREPARATION, PURIFICATION AND USE
-
Page/Page column 118-119, (2011/08/04)
The invention provides boronic esters of Formula (I) wherein R1, R2, R3, and R4 are as described herein, and methods for the preparation and purification thereof.
PROTEASOME INHIBITORS AND METHODS OF USING THE SAME
-
Page/Page column 200, (2008/06/13)
The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.